Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Zhang, Tong ^a   Watson, David G ^a   Wang, Lijie ^a   Abbas, Muhammad ^a   Murdoch, Laura ^d   Bashford, Lisa ^c   Ahmad, Imran ^b,c   Lam, Nga Yee ^e   Ng, Anthony C F ^e   Leung, Hing Y ^b,c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d Glasgow Clinical Research Facility   (United Kingdom)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; TUMOR MARKER;

ACCURACY; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CREATININE URINE LEVEL; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLOMICS; MULTIVARIATE ANALYSIS; OSMOLALITY; PARTIAL LEAST SQUARES REGRESSION; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; REVERSED PHASE LIQUID CHROMATOGRAPHY; URINALYSIS; URINE RETENTION; AREA UNDER THE CURVE; CHEMICAL PHENOMENA; PROCEDURES; PROSTATIC NEOPLASMS; URINE;

AREA UNDER CURVE; BIOMARKERS, TUMOR; CHROMATOGRAPHY, LIQUID; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MALE; MASS SPECTROMETRY; METABOLOMICS; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 84879169165     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065880     Document Type: Article

References (40)

1. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, et al. (2012) The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab 15: 157-170.
2. Issaq HJ, Fox SD, Chan KC, Veenstra TD, (2011) Global proteomics and metabolomics in cancer biomarker discovery. Journal of Separation Science 34: 3484-3492.
3. Claudino WM, Goncalves PH, di Leo A, Philip PA, Sarkar FH, (2012) Metabolomics in cancer: A bench-to-bedside intersection. Crit Rev Oncol Hematol 84: 1-7.
4. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
5. Cavaliere B, Macchione B, Monteleone M, Naccarato A, Sindona G, et al. (2011) Sarcosine as a marker in prostate cancer progression: a rapid and simple method for its quantification in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry. Anal Bioanal Chem 400: 2903-2912.
6. Wu H, Liu T, Ma C, Xue R, Deng C, et al. (2011) GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biobiomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem 401: 635-646.
7. Darbon JM, (2009) [Analysis of the metabolome suggests a major potential role of sarcosine in the progression of cancer of the prostate]. Bull Cancer 96: 355-356.
8. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, et al. (2010) Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 58: 12-18.
9. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, et al. (2011) Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 185: 706-711.
10. Issaq HJ, Veenstra TD, (2011) Is sarcosine a biomarker for prostate cancer? Journal of Separation Science 34: 3619-3621.
11. Schalken JA, (2010) Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 58: 19-20.
12. Bohm L, Serafin AM, Fernandez P, Van der Watt G, Bouic PJ, et al. (2012) Plasma sarcosine does not distinguish early and advanced stages of prostate cancer. S Afr Med J 102: 677-679.
13. Miyake M, Gomes Giacoia E, Aguilar Palacios D, Rosser CJ, (2012) Sarcosine, a biomarker for prostate cancer: ready for prime time? Biomark Med 6: 513-514.
14. Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, et al. (2012) Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 72: 1611-1621.
15. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA, (2010) Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 47: 282.
16. Martinez-Lozano P, Criado E, Vidal G, Cristoni S, Franzoso F, et al. (2011) Differential mobility analysis-mass spectrometry coupled to XCMS algorithm as a novel analytical platform for metabolic profiling. Metabolomics Online First™.
17. Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, et al. (2010) Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 5: e14175.
18. Trock BJ, (2011) Application of metabolomics to prostate cancer. Urol Oncol 29: 572-581.
19. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, et al. (2009) Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 8: 558-570.
20. Ganti S, Weiss RH, (2011) Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol 29: 551-557.
21. Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, et al. (2008) Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 179: 2422-2426.
22. Huang Z, Chen Y, Huang W, Gao Y, Lin L, et al. (2012) Holistic metabonomic profiling of urine affords potential early diagnosis for bladder and kidney cancers. Metabolomics Online First™.
23. Woo HM, Kim KM, Choi MH, Jung BH, Lee J, et al. (2009) Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 400: 63-69.
24. Chen J, Wang W, Lv S, Yin P, Zhao X, et al. (2009) Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta 650: 3-9.
25. Zhang T, Creek DJ, Barrett MP, Blackburn G, Watson DG, (2012) Evaluation of coupling reversed phase, aqueous normal phase, and hydrophilic interaction liquid chromatography with Orbitrap mass spectrometry for metabolomic studies of human urine. Anal Chem 84: 1994-2001.
26. Ryan D, Robards K, Prenzler PD, Kendall M, (2011) Recent and potential developments in the analysis of urine: a review. Anal Chim Acta 684: 8-20.
27. Warrack BM, Hnatyshyn S, Ott KH, Reily MD, Sanders M, et al. (2009) Normalization strategies for metabonomic analysis of urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 877: 547-552.
28. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, et al. (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 6: 1060-1083.
29. Chan EC, Pasikanti KK, Nicholson JK, (2011) Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nat Protoc 6: 1483-1499.
30. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, et al. (2010) Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc 5: 1005-1018.
31. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Clinical Chemistry 49: 1-6.
32. Pluskal T, Castillo S, Villar-Briones A, Oresic M, (2010) MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 11: 395.
33. Theodorides G, Gika GH, Wilson DI, (2011) Mass Spectrometry-based Holistic Analytical Approaches for Metabolite Profiling In Systems Biology Studies. Mass Spectrometry Reviews 30: 884-906.
34. Bylesjo M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, et al. (2006) OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. Journal of Chemometrics 20: 341-351.
35. Kuhara T, Ohse M, Inoue Y, Shinka T, (2009) Five cases of beta-ureidopropionase deficiency detected by GC/MS analysis of urine metabolome. J Mass Spectrom 44: 214-221.
36. Ide H, Petrullo LA, Hatahet Z, Wallace SS, (1991) Processing of DNA base damage by DNA polymerases. Dihydrothymine and beta-ureidoisobutyric acid as models for instructive and noninstructive lesions. J Biol Chem 266: 1469-1477.
37. Wallace SS, (2002) Biological consequences of free radical-damaged DNA bases. Free Radic Biol Med 33: 1-14.
38. Bjelland S, Seeberg E, (2003) Mutagenicity, toxicity and repair of DNA base damage induced by oxidation. Mutat Res 531: 37-80.
39. Marklova E, (1999) Where does indolylacrylic acid come from? Amino Acids 17: 401-413.
40. Abdenur JE, Abeling N, Specola N, Jorge L, Schenone AB, et al. (2006) Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab 87: 48-53.